NewsBenzingaLas acciones de Belite Bio se desploman después de que la FDA amplía el plazo de revisión Las acciones de Belite Bio se desploman después de que la FDA amplía el plazo de revisión Benzinga 2026.11.20 15:12 (GMT+0) Open on Benzinga Other news The Biggest Winners from the Anthropic IPO Could Be Everyday SPY Investors Bitdeer (BTDR) Stock Falls 15.21% Intraday, Now at $2.89 Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript Wells Fargo Maintains Overweight on California Resources, Raises Price Target to $77 B. Riley Securities Reiterates Buy on Orchestra BioMed Hldgs, Raises Price Target to $12 PerpetualCow: $13 Million XMR Theft Traced to Compromise of Hosting Provider 1984
Bausch + Lomb Corporation (BLCO) Discusses Phase II Results for BL1332 in Ocular Surface Pain Transcript